Oppenheimer & Co. Inc. Has $1.91 Million Holdings in Biogen Inc. $BIIB

Oppenheimer & Co. Inc. boosted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 501.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,610 shares of the biotechnology company’s stock after purchasing an additional 11,346 shares during the period. Oppenheimer & Co. Inc.’s holdings in Biogen were worth $1,906,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Elevation Point Wealth Partners LLC bought a new position in shares of Biogen in the second quarter valued at about $25,000. Rothschild Investment LLC grew its holdings in Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 88 shares during the last quarter. NewSquare Capital LLC increased its position in Biogen by 134.6% in the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 140 shares in the last quarter. WFA of San Diego LLC acquired a new stake in Biogen in the 2nd quarter valued at about $32,000. Finally, True Wealth Design LLC raised its stake in shares of Biogen by 62.9% in the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Insider Transactions at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.18% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on BIIB shares. Truist Financial increased their price target on shares of Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a research note on Monday, February 9th. Jefferies Financial Group increased their price objective on Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a research report on Friday, November 28th. Robert W. Baird lowered their target price on Biogen from $255.00 to $250.00 in a research note on Friday, October 31st. Wolfe Research set a $231.00 price target on Biogen in a research note on Monday. Finally, UBS Group assumed coverage on Biogen in a report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 price target on the stock. Twelve equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $205.84.

Biogen Trading Up 0.5%

NASDAQ BIIB opened at $196.52 on Friday. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $202.41. The stock has a 50-day simple moving average of $178.22 and a 200 day simple moving average of $158.85. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $28.84 billion, a PE ratio of 22.31, a P/E/G ratio of 1.55 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company’s revenue was down 7.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.